Literature DB >> 15505701

French-Canadian version of the Chronic Respiratory and St George's Respiratory questionnaires: an assessment of their psychometric properties in patients with chronic obstructive pulmonary disease.

Jean Bourbeau1, Francois Maltais, Michel Rouleau, Chantal Guímont.   

Abstract

BACKGROUND: French versions of the Chronic Respiratory Questionnaire (CRQ) and the St George's Respiratory Questionnaire (SGRQ) have largely been used in Canada, although the process by which they were translated remains unknown and the psychometric properties of these translated versions have not been assessed in a properly designed study.
OBJECTIVE: To translate and evaluate the psychometric properties of the French-Canadian versions of the CRQ and the SGRQ.
METHODS: The questionnaires were translated according to standardized guidelines for cross-cultural adaptation. Measurements were made at baseline and again after two weeks in 27 chronic obstructive pulmonary disease (COPD) patients known to have stable disease. Measurements were also taken pre- and post-treatment in patients with acute exacerbation of COPD (33 patients) or in pulmonary rehabilitation (32 patients).
RESULTS: The CRQ showed high test-retest reliability (the majority above 0.70), although it was slightly lower for the dyspnea dimension (0.58 to 0.65). The SGRQ also showed high test-retest reliability (above 0.80), although it was lower for the symptoms dimension (0.54 to 0.58). The internal consistency reliability coefficients ranged from 0.73 to 0.90 for the CRQ and above 0.80 for the SGRQ, except for the symptoms dimension. The Pearson's correlation coefficients were low (less than 0.30) between most of the translated questionnaire dimension scores and forced expiratory volume in 1 s, 6 min walking test and dyspnea measures. The correlation was generally high (greater than 0.50) between the two questionnaires and the 36-item short form health survey, and for those domains that measured the same construct. The changes in the total and subscale scores of the CRQ and the SGRQ (except for the symptoms domain) were all largely above the variability of the score in the stable disease group.
CONCLUSION: The present study confirms that the French-Canadian translated versions of the CRQ and the SGRQ perform well with respect to their psychometric properties. They are both suitable for their intended purpose, ie, to detect change in health status in patients with COPD when assessing if a treatment is beneficial. However, the symptoms domain of the SGRQ cannot be used to assess acute change with respect to a given therapy.

Entities:  

Mesh:

Year:  2004        PMID: 15505701     DOI: 10.1155/2004/702421

Source DB:  PubMed          Journal:  Can Respir J        ISSN: 1198-2241            Impact factor:   2.409


  16 in total

1.  Chronic obstructive pulmonary disease in women.

Authors:  Louis Laviolette; Yves Lacasse; Mariève Doucet; Miriam Lacasse; Karine Marquis; Didier Saey; Pierre Leblanc; François Maltais
Journal:  Can Respir J       Date:  2007-03       Impact factor: 2.409

2.  Validation of a new questionnaire with generic and disease-specific qualities: the McGill COPD Quality of Life Questionnaire.

Authors:  Smita Pakhale; Sharon Wood-Dauphinee; Adriana Spahija; Jean-Paul Collet; Francois Maltais; Sarah Bernard; Marc Baltzan; Michel Rouleau; Jean Bourbeau
Journal:  Can Respir J       Date:  2012 Nov-Dec       Impact factor: 2.409

3.  Health status in COPD cannot be measured by the St George's Respiratory Questionnaire alone: an evaluation of the underlying concepts of this questionnaire.

Authors:  Leonie Daudey; Jeannette B Peters; Johan Molema; P N Richard Dekhuijzen; Judith B Prins; Yvonne F Heijdra; Jan H Vercoulen
Journal:  Respir Res       Date:  2010-07-22

4.  COPD-Specific Self-Management Support Provided by Trained Educators in Everyday Practice is Associated with Improved Quality of Life, Health-Directed Behaviors, and Skill and Technique Acquisition: A Convergent Embedded Mixed-Methods Study.

Authors:  Myriam Gagné; Sophie Lauzier; Justine Babineau-Therrien; Christine Hamel; Sara-Edith Penney; Jean Bourbeau; Jocelyne Moisan; Louis-Philippe Boulet
Journal:  Patient       Date:  2020-02       Impact factor: 3.883

5.  The impact of obesity on walking and cycling performance and response to pulmonary rehabilitation in COPD.

Authors:  Francesco Sava; Louis Laviolette; Sarah Bernard; Marie-Josée Breton; Jean Bourbeau; François Maltais
Journal:  BMC Pulm Med       Date:  2010-11-06       Impact factor: 3.317

6.  The reliability of an Arabic version of the self-administered standardized chronic respiratory disease questionnaire (CRQ-SAS).

Authors:  Mohamed S Al Moamary; Hani M Tamim
Journal:  BMC Pulm Med       Date:  2011-04-28       Impact factor: 3.317

Review 7.  Combining scores from different patient reported outcome measures in meta-analyses: when is it justified?

Authors:  Milo A Puhan; Irene Soesilo; Gordon H Guyatt; Holger J Schünemann
Journal:  Health Qual Life Outcomes       Date:  2006-12-07       Impact factor: 3.186

8.  Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD.

Authors:  A-B Tonnel; T Perez; J-M Grosbois; C Verkindre; M-L Bravo; M Brun
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

9.  Inspiratory muscle training protocol for patients with chronic obstructive pulmonary disease (IMTCO study): a multicentre randomised controlled trial.

Authors:  Noppawan Charususin; Rik Gosselink; Marc Decramer; Alison McConnell; Didier Saey; Francois Maltais; Eric Derom; Stefanie Vermeersch; Hanneke van Helvoort; Yvonne Heijdra; Mariska Klaassen; Rainer Glöckl; Klaus Kenn; Daniel Langer
Journal:  BMJ Open       Date:  2013-08-05       Impact factor: 2.692

10.  Clinical characteristics and quality of life in women with COPD: an observational study.

Authors:  Chantal Raherison; Isabelle Tillie-Leblond; Anne Prudhomme; Camille Taillé; Elisabeth Biron; Cecilia Nocent-Ejnaini; Benigne Mathieu; Juliette Ostinelli
Journal:  BMC Womens Health       Date:  2014-02-20       Impact factor: 2.809

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.